BIO 140Alternative Names: Lumencin
Latest Information Update: 25 Mar 2008
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Iodinated contrast media
- Mechanism of Action Emission-computed tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Cardiovascular disorders (diagnosis) in USA (unspecified route)
- 21 Jan 2003 Preclinical trials in Cardiovascular disorders (diagnosis) in USA (unspecified route)